PNC Managed Account Solutions’s Sarepta Therapeutics SRPT Stock Holding History

PNC Managed Account Solutions’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$13K	Buy	+173	New	+$13.1K	﹤0.01%	449

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PNC Managed Account Solutions's SRPT Position: Q2 2021 in Review

PNC Managed Account Solutions opened a new position in Sarepta Therapeutics (SRPT) in Q2 2021: 173 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #449 among its holdings.

330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

PNC Managed Account Solutions held 173 shares of Sarepta Therapeutics worth $13K as of Q2 2021.
Sarepta Therapeutics was a new PNC Managed Account Solutions position in Q2 2021.
Sarepta Therapeutics made up ﹤0.01% of PNC Managed Account Solutions's portfolio in Q2 2021, its #449 holding.
330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on PNC Managed Account Solutions's 13F filing for Q2 2021, filed 6 Aug 2021.